- About Mesothelioma
- Mesothelioma Cause
- Mesothelioma Symptoms
- Mesothelioma Diagnosis
- Mesothelioma Stages
NEWS ABOUT PHARMACEUTICALS IN MESOTHELIOMA TREATMENT
- Nanoparticles Could Deliver Cancer Drugs
- Meta-analysis of cancer clinical trials finds 41 percent are superior to existing treatments
- Vinflunine Shows Promise in Treating Malignant Pleural Mesothelioma
- Synthetic Molecules Could Offer A Lower Cost Cancer Treatment Alternative
- "Bacteria Therapy" Shows Promise in Initial Tests
- New UCLA Machine May Kill Cancer Cells
- Study raises doubts about some DNA-based drugs
- Disease-Causing Bugs May Help Treat Cancer
- New Cancer Vaccine Approved for Limited Use in Russia
- New Therapy Targets Hepatitis C
- Innovative New Cancer Treatment Idea Earns $1 Million Prize
- Higher Doses of Chemotherapy Make No Difference in Small Cell Lung Cancer
- Nanoparticles Help Advance Anticancer siRNA Therapy
- Research at MIT Shows microRNA's Protective Role
- Patients See Benefit From Self Reporting Symptoms Online
- Cancer drugs from genetically modified chicken eggs
- Researchers attempting to figure out how cancer grows
- Antifolates - Chemotherapy drugs
- Dopamine for cancer treatment
- Concerns about anemia medications for cancer patients
- Researchers Developing New Ways of Detecting Cancer
- Recentin Study Ends
- Phase II Study of Sutent ® Results Out
- Terminally Ill Cancer Patients Given Hope in UK
- New Finding on Correlation Between Angiogenesis, Breast Cancer and Inflammation
- PET Found to be effective in the Evaluation of Cancer Treatment
- One-tird of cancer patients experience chronic fatigue after treatment
- New Drug Cocktails Hold Promise for Cancer, HIV Treatments.
- New DNA Discovery Changes the Way Doctors Look at Cancer.
- Inraperitoneal Hyperthermic Chemotherapy for Those Suffering With Abdominal Cancer
- Mouse Model For Mesothelioma Reproduces Human Disease
- Researchers Use Transcriptome Analysis by 454 Sequencing to Identify Tumor Specific Mutations Linked to Malignant Pleural Mesothelioma
- Pre-Clinical Data Show Intracellular Pathways Affected by Onconase
- Remembering a researcher’s legacy on asbestos research
- PET proves effective in evaluating cancer treatment
- Trial on experimental antifolate PDX (Pralatrexate)
- American College of Physicians releases guidelines for end-of-life care
- Web-based system helps doctors track outpatients’ chemotherapy toxicity
- NICE Gives Final Approval for Alimta
- Par Pharmaceuticals licenses Onconase
- Thalidomide and Alimta to be Combined in New Clinical Trial
- Alfacell Updates Status Of ONCONASE(R) Phase III Clinical Program
- ONCONASE(R) has Potential as Chemopreventive Agent in Mesothelioma
- Boysenberries might impede mesothelioma
- Diagnostic Tools For Lung And Mesothelioma Cancers To Be Developed
- New Mesothelioma Research Center to Open in Sydney
- Virotherapy to Treat Mesothelioma
- MIT researchers' "nanocell" delivers a toxic double whammy to tumors
- FDA Approves the MESOMARK® Assay for the Management of Mesothelioma Patients
- NYU School of Medicine Verifies Mesothelioma Diagnostic Test
- Researchers Identify Intracellular Pathway of Alfacell's Onconase
- New Study
Heralds Shortened Timeline for Anticancer Drug Development
- Talcum Powder Stunts Tumor Growth
- Soluble mesothelin in effusions a strong indicator of mesothelioma
- Diagnostic Tools For Lung And Mesothelioma Cancers To Be Developed
- New Technology For Cancer Screening Listens For The Signs Of Cancer
- Onconase(®) is in its final phase 3 trial for treatment of patients with unresectable malignant mesothelioma
- Data Affirm Benefit of ALIMTA(®) for Patients With Malignant Pleural Mesothelioma
- New diagnostic tool for mesothelioma to be developed: test will extract microRNAs from a simple blood draw
- The Barbara Ann Karmanos Cancer Institute announces significant scientific findings related to Malignant Mesothelioma
- Mild Hyperthermia Enhances Antitumor Effects of Ranpirnase
- Study shows Mesomark effective for monitoring Mesothelioma
- FDA Grants Orphan Drug status to Onconase for Mesothelioma
- Alfacell Corporation Files for U.S. Orphan Drug Designation for Onconase
- Additional Data From a Phase I Trial of XL647 in Patients With Advanced Solid Tumors
- New study on the safety, tolerability, pharmacokinetics and preliminary efficacy of INNO-305
- More evidence that patients treated with Onconase have greater median survival times than patients treated with doxorubicin alone
- Zolinza becomes first approved HDAC inhibitor
- Alimta Researchers Recognized As Heroes Of Chemistry
- Progress on Clinical Development Program for ONCONASE(R) in Malignant Mesothelioma
- FDA tells Eli Lilly that their Alimta brochure is misleading
- News about onocology product candidate SS1P (renamed CAT-5001)
- New Research Shows Unique Promise of Onconase in the Prevention and Treatment of Mesothelioma
- CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for Mesothelioma
- Alfacell Provides Update on ONCONASE Phase IIIb Confirmatory Registration Trial; Releases First Interim Analysis Data
- Alfacell Achieves Full Patient Enrollment Milestone for the Onconase Phase IIIb Registration Study in Unresectable Malignant Mesothelioma
- Scientist Reveals His Hopes for Better Tumour Treatment
- Alfacell Drug Trial Ahead of Schedule
- Alfacell Forms New Thoracic Cancer Advisory Board
- Update on Onconase Clinical Program
- Promising Research in Early Detection of Mesothelioma
- Morphotek Announces IND Submission for MORAb-009, a Monoclonal Antibody for the Treatment of Mesothelin-Expressing Cancers
- INNOVIVE Pharmaceuticals Licenses WT1 Peptide Cancer Immunotherapeutic from Memorial Sloan-Kettering Cancer Center
- Gene Drug Gives Mesothelioma Patient Second Chance
- Novel therapies for pleural mesothelioma
- Thoracic Cancer Patients Find New Reasons for Hope with Alimta(®)
Read excerpts from medical publications
Contact Us
News
- Mesothelioma News
- International News
- Pharmaceutical News
- Environmental News
- Medical Journal Articles
Resources
- Leading Cancer Links
- Financial Assistance, Compensation, and Legal Rights
- Disclaimer and Sponsorship Information
If you would like to receive a FREE information packet or have questions about mesothelioma, call us at:
Toll-Free 1-877-367-6376


